Its technology-centric solutions enable hospitals to enhance operational efficiency and enable faster clinical decision making
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Govt announces vaccination programme for kids and those above 60 years of age
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package)
It is only the second generic application approved by the USFDA
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
A total of 49 projects have been approved so far for 33 critical APIs with a committed investment of Rs 3,685 crore
Subscribe To Our Newsletter & Stay Updated
